Pfizer expects 2023 sales to decline as much as 33% compared with record-breaking 2022
Publishing timestamp: 2023-01-31 11:05:46
Summary
Pfizer forecasted a significant drop in revenue for 2023 compared to their record-breaking 2022 results. They expect $13.5 billion in Covid vaccine sales and $8 billion in revenue for Paxlovid. Earnings are expected to drop by as much as 50%. The fourth quarter largely met analyst expectations. The FDA proposed new lead limits for baby food and Bill Gates commented on the global response to the pandemic. GenBioPro is suing West Virginia over a state ban.
Sentiment: MIXED
Tickers: PFE,
Keywords: biotechnology, pandemics, coronavirus, epidemics, disease outbreaks, business, pfizer inc, u.s. economy, breaking news: business, health care industry, biotech and pharmaceuticals, politics, business news,
Source: https://www.cnbc.com/2023/01/31/pfizer-pfe-q4-earnings-2022.html